A Phase 2 Randomized, Double-Blind, Placebo–Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis*

Overview of attention for article published in Critical Care Medicine, March 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

blogs: 1 blog
twitter: 15 X users
patent: 6 patents

facebook: 2 Facebook pages
f1000: 1 research highlight platform

Readers on

mendeley: 147 Mendeley

So far, Altmetric has seen 18 X posts from 15 X users, with an upper bound of 147,898 followers.

Sustained survival in severe sepsis with enteral talactoferrin alfa #CCMJournal http://t.co/Pq0B2EXd30

RT @SCCM: Sustained survival in severe sepsis with enteral talactoferrin alfa #CCMJournal http://t.co/Pq0B2EXd30

Sustained survival in severe sepsis with enteral talactoferrin alfa #CCMJournal http://t.co/Pq0B2EXd30

“@SCCM: Sustained survival in severe sepsis with enteral talactoferrin alfa #CCMJournal http://t.co/nCWgEkphZ4” OMG APC RETURNS #sepsis

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 14 additional X posts.